Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance
Rapid Micro Biosystems (Nasdaq: RPID) reported third quarter 2025 results and updated guidance. Q3 revenue was $7.8 million, up 3% year-over-year, with recurring revenue +32% to $4.8 million and record consumable sales. The company posted a Q3 gross margin of 9% and a net loss of $11.5 million (EPS $0.26). Cash, equivalents and short-term investments were about $42 million as of September 30, 2025.
In October, the company received its largest multi-system order from a Top 20 global biopharma to place systems across North America, Europe and Asia Pacific. Rapid Micro raised full-year 2025 revenue guidance to at least $33.0 million, assuming at least 27 Growth Direct placements.
Rapid Micro Biosystems (Nasdaq: RPID) ha riportato i risultati del terzo trimestre 2025 e aggiornato le previsioni. Le entrate del Q3 sono state di 7,8 milioni di dollari, in aumento del 3% rispetto all'anno precedente, con ricavi ricorrenti +32% a 4,8 milioni e vendite record di consumabili. L'azienda ha registrato un margine lordo del Q3 del 9% e una perdita netta di 11,5 milioni di dollari (EPS 0,26). Il cash, gli equivalenti e gli investimenti a breve termine erano circa 42 milioni di dollari al 30 settembre 2025.
In ottobre, l'azienda ha ricevuto il suo più grande ordine multi-sistema da un Top 20 globale biopharma per posizionare sistemi in Nord America, Europa e Asia Pacifico. Rapid Micro ha aumentato le previsioni di fatturato per tutto il 2025 a almeno 33,0 milioni di dollari, supponendo almeno 27 installazioni Growth Direct.
Rapid Micro Biosystems (Nasdaq: RPID) presentó los resultados del tercer trimestre de 2025 y actualizó las previsiones. Los ingresos del Q3 fueron de 7,8 millones de dólares, un aumento del 3% interanual, con ingresos recurrentes +32% a 4,8 millones y ventas récord de consumibles. La empresa registró un margen bruto del Q3 del 9% y una pérdida neta de 11,5 millones de dólares (EPS 0,26). El efectivo, equivalentes e inversiones a corto plazo fueron alrededor de 42 millones de dólares al 30 de septiembre de 2025.
En octubre, la empresa recibió su mayor pedido multi-sistema de un biopharma global del Top 20 para colocar sistemas en Norteamérica, Europa y Asia Pacífico. Rapid Micro elevó las previsiones de ingresos para todo 2025 a al menos 33,0 millones de dólares, suponiendo al menos 27 instalaciones Growth Direct.
Rapid Micro Biosystems (나스닥: RPID)는 2025년 3분기 실적을 발표하고 가이던스를 업데이트했습니다. 3분기 매출은 790만 달러로 전년 동기 대비 3% 증가했으며 반복 매출 +32%를 480만 달러로 달성했고 소모품 매출은 사상 최고치였습니다. 회사의 3분기 총이익률은 9%였고 순손실은 1150만 달러(EPS 0.26)였습니다. 현금, 현금등가물 및 단기투자는 2025년 9월 30일 기준 약 4200만 달러였습니다.
10월에 이 회사는 글로벌 바이오의약품 상위 20대 가운데 최대 규모의 다중 시스템 주문을 받았고 북미, 유럽 및 아시아 태평양에 시스템을 배치했습니다. Rapid Micro는 2025년 연간 매출 가이던스를 최소 3300만 달러로 상향했으며, Growth Direct 설치 최소 27대를 가정했습니다.
Rapid Micro Biosystems (Nasdaq : RPID) a publié les résultats du troisième trimestre 2025 et a revu ses prévisions. Le chiffre d'affaires du T3 s'est élevé à 7,8 millions de dollars, en hausse de 3% d'une année sur l'autre, avec un chiffre d'affaires récurrent +32% à 4,8 millions et des ventes record de consommables. La société a enregistré une marge brute du T3 de 9% et une perte nette de 11,5 millions de dollars (EPS 0,26). La trésorerie, les équivalents et les investissements à court terme s'élevaient à environ 42 millions de dollars au 30 septembre 2025.
En octobre, l'entreprise a reçu sa plus grande commande multi-système d'un biopharma mondial du Top 20 pour déployer des systèmes en Amérique du Nord, en Europe et en Asie-Pacifique. Rapid Micro a relevé ses prévisions pour l'ensemble de l'année 2025 à au moins 33,0 millions de dollars, en supposant au moins 27 installations Growth Direct.
Rapid Micro Biosystems (Nasdaq: RPID) meldete die Ergebnisse des dritten Quartals 2025 und aktualisierte die Guidance. Q3-Umsatz betrug 7,8 Mio. USD, ein Anstieg von 3% gegenüber dem Vorjahr, mit wiederkehrenden Umsätzen +32% auf 4,8 Mio. USD und Rekordverkäufen von Verbrauchsmaterialien. Das Unternehmen verzeichnete eine Q3-Bruttomarge von 9% und einen Nettoverlust von 11,5 Mio. USD (EPS 0,26). Kasse, Äquivalente und kurzfristige Anlagen beliefen sich zum 30. September 2025 auf ca. 42 Mio. USD.
Im Oktober erhielt das Unternehmen seinen größten Multi-System-Auftrag von einem der Top-20-globalen Biopharma-Unternehmen, um Systeme in Nordamerika, Europa und dem asiatisch-pazifischen Raum zu platzieren. Rapid Micro hob die Jahresumsatzprognose 2025 auf mindestens 33,0 Mio. USD an, vorausgesetzt werden mindestens 27 Growth Direct-Installationen.
Rapid Micro Biosystems (ناسداك: RPID) أصدرت نتائج الربع الثالث من 2025 وكرّست التوجيه. إيرادات الربع الثالث بلغت 7.8 مليون دولار، بزيادة قدرها 3% على أساس سنوي، مع إيرادات متكررة +32% إلى 4.8 مليون دولار ومبيعات استهلاكية قياسية. سجلت الشركة هامش إجمالي للربع الثالث بنسبة 9% وخسارة صافية قدرها 11.5 مليون دولار (ربحية للسهم 0.26). كانت السيولة النقدية وما يعادلها والاستثمارات قصيرة الأجل نحو 42 مليون دولار حتى 30 سبتمبر 2025.
في أكتوبر، تلقت الشركة أكبر طلب متعدد الأنظمة من شركة أحيائية مدرجة ضمن أفضل 20 عالميًا لتوزيع الأنظمة في أمريكا الشمالية وأوروبا ومنطقة آسيا والمحيط الهادئ. رفعت Rapid Micro توقعات الإيرادات للسنة المالية 2025 إلى ما لا يقل عن 33.0 مليون دولار، مع افتراض وجود لا يقل عن 27 تركيب Growth Direct.
- Recurring revenue increased 32% YoY to $4.8M
- Raised 2025 revenue guidance to at least $33.0M
- Guidance assumes at least 27 Growth Direct system placements
- Largest multi-system order received from a Top 20 global biopharma across NA, Europe, APAC
- Service revenue grew 12% YoY to $2.6M
- Net loss of $11.5M in Q3 2025
- Product revenue essentially flat YoY at $5.2M
Insights
Record consumables, a largest-ever multi-system order and raised guidance point to constructive commercial momentum.
The business shows strengthening recurring revenue with record consumable sales and a
Key dependencies and risks include execution on the announced multi-system rollout across North America, Europe and Asia Pacific and the company’s ability to convert the order into placements and consumable consumption. The quarter still shows a net loss (
Watch placement and consumable ramp in the fourth quarter and early
- Reports third quarter 2025 total revenue of
$7.8 million , representing3% growth compared to the third quarter of 2024.- Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased
32% compared to the third quarter of 2024 driven by record consumable revenue.
- Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased
- Reports third quarter gross margin of
9% , representing a 70-basis point improvement compared to the third quarter of 2024. - Announces record multi-system order from an existing Top 20 global biopharma customer to automate global manufacturing network.
- Raises full year 2025 total revenue guidance to at least
$33.0 million , which assumes at least 27 Growth Direct system placements.
LEXINGTON, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2025.
"Our third quarter results once again reflected strong and consistent execution across the business," said Robert Spignesi, President and CEO. "We delivered record consumable revenue and double-digit service growth, and system placements were in line with our expectations. Recurring revenue increased more than
"We are also pleased to announce that, in October, we received our largest multi-system order in company history from an existing Top 20 global biopharma customer," continued Spignesi. "This follow-on purchase, which includes existing and new sites for this customer in North America, Europe and Asia Pacific, underscores the continued growing adoption of the Growth Direct platform in large-scale, global pharmaceutical manufacturing, reinforces the trust our customers place in us, and supports our outlook for growth in 2026 and beyond."
Third Quarter Financial Results
Total revenue for the third quarter of 2025 increased
Total cost of revenue was
Total operating expenses decreased by
Net loss for the third quarter of 2025 was
Cash, cash equivalents, short-term investments, and restricted cash were approximately
Record Multi-System Customer Order
In October, the Company received the largest multi-system customer order in its history from an existing Top 20 global biopharma customer. The systems will be placed across manufacturing sites in North America, Europe and Asia Pacific and include environmental monitoring, water and bioburden applications.
2025 Outlook
The Company is raising its full year 2025 total revenue guidance to at least
Webcast Details
The Company will host a conference call before the market opens today, November 7, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results. The live call is accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Rapid Micro Biosystems intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities and Exchange Commission (“SEC”), public conference calls, presentations and webcasts.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance, including with respect to full year 2025 total revenue and number of Growth Direct placements; and the Company's growth outlook in future periods.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the Company's ability to fulfill customer orders on its anticipated timelines or at all; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
| RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue: | |||||||||||||||
| Product revenue | $ | 5,214 | $ | 5,255 | $ | 14,117 | $ | 13,505 | |||||||
| Service revenue | 2,624 | 2,349 | 8,188 | 6,328 | |||||||||||
| Total revenue | 7,838 | 7,604 | 22,305 | 19,833 | |||||||||||
| Costs and operating expenses: | |||||||||||||||
| Cost of product revenue | 5,563 | 5,314 | 15,907 | 15,404 | |||||||||||
| Cost of service revenue | 1,579 | 1,668 | 5,023 | 5,519 | |||||||||||
| Research and development | 3,529 | 3,609 | 10,383 | 11,195 | |||||||||||
| Sales and marketing | 2,895 | 3,376 | 8,760 | 10,284 | |||||||||||
| General and administrative | 5,644 | 5,676 | 17,413 | 17,121 | |||||||||||
| Total costs and operating expenses | 19,210 | 19,643 | 57,486 | 59,523 | |||||||||||
| Loss from operations | (11,372 | ) | (12,039 | ) | (35,181 | ) | (39,690 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest income | 347 | 779 | 1,188 | 2,617 | |||||||||||
| Interest expense | (393 | ) | (11 | ) | (417 | ) | (28 | ) | |||||||
| Other expense | (79 | ) | (39 | ) | (190 | ) | (91 | ) | |||||||
| Total other income (expense), net | (125 | ) | 729 | 581 | 2,498 | ||||||||||
| Loss before income taxes | (11,497 | ) | (11,310 | ) | (34,600 | ) | (37,192 | ) | |||||||
| Income tax expense | 8 | 13 | 26 | 31 | |||||||||||
| Net loss | $ | (11,505 | ) | $ | (11,323 | ) | (34,626 | ) | (37,223 | ) | |||||
| Net loss per share — basic and diluted | $ | (0.26 | ) | $ | (0.26 | ) | $ | (0.78 | ) | $ | (0.86 | ) | |||
| Weighted average common shares outstanding — basic and diluted | 44,956,131 | 43,668,656 | 44,534,826 | 43,510,911 | |||||||||||
| RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Balance Sheets (in thousands) | |||||
| September 30, 2025 | December 31, 2024 | ||||
| Assets | |||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 18,946 | $ | 16,911 | |
| Short-term investments | 22,302 | 33,821 | |||
| Accounts receivable | 5,430 | 7,519 | |||
| Inventory | 21,068 | 20,200 | |||
| Prepaid expenses and other current assets | 2,205 | 2,466 | |||
| Total current assets | 69,951 | 80,917 | |||
| Property and equipment, net | 9,584 | 11,193 | |||
| Right-of-use assets, net | 4,377 | 5,163 | |||
| Other long-term assets | 211 | 531 | |||
| Restricted cash | 284 | 365 | |||
| Total assets | $ | 84,407 | $ | 98,169 | |
| Liabilities and Stockholders’ Equity | |||||
| Current liabilities: | |||||
| Accounts payable | $ | 3,592 | $ | 2,535 | |
| Accrued expenses and other current liabilities | 6,608 | 7,217 | |||
| Deferred revenue | 5,070 | 6,599 | |||
| Lease liabilities, short-term | 1,277 | 1,214 | |||
| Total current liabilities | 16,547 | 17,565 | |||
| Lease liabilities, long-term | 4,002 | 4,954 | |||
| Notes payable, net | 18,828 | — | |||
| Warrant liability | 358 | — | |||
| Other long-term liabilities | 340 | 298 | |||
| Total liabilities | 40,075 | 22,817 | |||
| Total stockholders’ equity | 44,332 | 75,352 | |||
| Total liabilities and stockholders’ equity | $ | 84,407 | $ | 98,169 | |
| RAPID MICRO BIOSYSTEMS, INC. Unaudited Cash, Cash Equivalents and Investments (in thousands) | |||||
| September 30, 2025 | December 31, 2024 | ||||
| Cash and cash equivalents | $ | 18,946 | $ | 16,911 | |
| Short-term investments | 22,302 | 33,821 | |||
| Restricted cash | 284 | 365 | |||
| Cash, cash equivalents and investments | $ | 41,532 | $ | 51,097 | |
Investor Contact Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact media@rapidmicrobio.com
FAQ
What were Rapid Micro Biosystems (RPID) Q3 2025 revenues and recurring revenue?
How did Rapid Micro Biosystems (RPID) change its full-year 2025 guidance on November 7, 2025?
What is the significance of the record multi-system order announced by Rapid Micro (RPID)?
How many Growth Direct systems did Rapid Micro (RPID) place in Q3 2025?
What was Rapid Micro Biosystems' (RPID) Q3 2025 net loss and EPS?
How much cash did Rapid Micro Biosystems (RPID) report at September 30, 2025?
